MARIPOSA: Amivantamab Plus Lazertinib Versus Osimertinib in EGFR-mutant NSCLC

Results from the phase 3 MARIPOSA trial show that amivantamab plus lazertinib is the “first and only treatment to significantly reduce the risk of death” compared to osimertinib in the first-line treatment of patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to study investigators.

The combination therapy “demonstrated a statistically significant and clinically meaningful improvement” in OS for patients with previously untreated advanced NSCLC with EGFR exon 19 deletions or L858R substitution mutations. At a median follow-up of nearly 38 months, 60% of patients in the combination arm were alive at 3 years, compared to 51% in the osimertinib arm.

Read more comments from Dr. Yang’s presentation at the European Lung Cancer Congress 2025.

Read the full MARIPOSA study.